Диссертация (1139785), страница 25
Текст из файла (страница 25)
Izzo JL Jr, Gradman AH / Mechanisms and management of hypertensive heartdisease: from left ventricular hypertrophy to heart failure // Med Clin North Am.2004;88 (5):1257–1271.125. Jarvis M. / Ultra-Sensitive Analysis of Aldosterone in Serum Using the AB SCIEXTripleQuad™6500LC/MS/MSSystem//Availablefrom:http://www.absciex.com/Documents/Downloads/Literature/6500_Aldosterone.pdf.126. Jones CG, Cleland JG. / Meeting report: the LIDO, HOPE, MOXCON and WASHstudies: Heart Outcomes Prevention Evaluation. The Warfarin/Aspirin Study of HeartFailure // Eur J Heart Fail. 1999;1 (4):425–431.127. Johnston D, Duffin D.
/ Drug-patient interactions and their relevance in thetreatment of heart failure // Am J Cardiol. 1992 Oct 8;70(10):109C-112C.128. Juurlink DN, Mamdani MM, Lee DS et al. / Rates of hyperkalemia afterpublication of the Randomized Aldactone Evaluation Study // N Engl J Med. 2004. 351(6):543–551.129. Kindsvater S, Leclerc K, Ward J.
/ Effects of coadministration of aspirin orclopidogrel on exercise testing in patients with heart failure receiving angiotensinconverting enzyme inhibitors // Am J Cardiol. 2003;91 (11):1350–1352.130. King JB, Bress AP, Reese AD, Munger MA / Neprilysin inhibition in heart failurewith reduced ejection fraction: a clinical review // Pharmacother J Hum Pharmacol DrugTher 2015. 35:823–837.131. Kjekshus J, Apetrei E, Barrios V, et al. / Rosuvastatin in older patients withsystolic heart failure // N Engl J Med 2007;357:2248–2261.132. Kleber FX, Doering W.
/ Prognosis of mild chronic heart failure: effects of theACE inhibitor captopril // Herz. 1991;16 Spec No 1:283–293.134133. Kober L, Torp-Pedersen C, Carlsen JE et al. / A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunctionafter myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group //N Engl J Med. 1995. 333 (25):1670–1676.134. Konstam MA, Neaton J D, Dickstein K et al. / Eff ects of high-dose versus lowdose losartan on clinical outcomes in patients with heart failure (HEAAL study): arandomised, double-blind trial // Lancet. 2009;374 (9704):1840–1848.135.
Kramer DG, Trikalinos TA, Kent DM et al. / Quantitative evaluation of drug ordevice effects on ventricular remodeling as predictors of therapeutic effects on mortalityin patients with heart failure and reduced ejection fraction: a meta-analytic approach // JAm Coll Cardiol. 2010;56 (5):392–406.136. Kukes, V.G., Grachev, S.V., Sychev, D.A., Ramenskaya, G.V. / Metabolism ofdrugs. Scientific bases of personal medicine: A guide for medical practitioners //Moscow: GEOTAR Media; 2008.137.
Langenickel TH , Tsubouchi C, Ayalasomayajula S et al. / The effect of LCZ696on amyloid-β concentrations in cerebrospinal fluid in healthy subjects // Br J ClinPharmacol 2015 Dec 12.138. Lewis DF, Dickins M, Eddershaw PJ et al. / Cytochrome P450 substratespecificities, substrate structural templates and enzyme active site geometries // DrugMetabol Drug Interact. 1999;15(1):1-49139.
Linder MW, Prough RA, Valdes R Jr. / Pharmacogenetics: a laboratory tool foroptimizing therapeutic efficiency // Clin Chem. 1997 Feb;43(2):254-66.140. Lip GYH, Ponikowski P, Andreotti F et al. / Thrombo-embolism andantithrombotic therapy for heart failure in sinus rhythm. A joint consensus documentfrom the ESC Heart Failure Association and the ESC Working Group on Thrombosis //Eur J Heart Fail 2012.14:681–695.141. Li X, Qi Y, Li Y et al. / Impact of mineralocorticoid receptor antagonists onchanges in cardiac structure and function of left ventricular dysfunction: a meta-analysisof randomized controlled trials // Circ Heart Fail. 2013;6 (2):156–165.135142.
Lown KS, Mayo RR, Leichtman AB et al. / Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporine // ClinPharmacol Ther. 1997 Sep;62(3):248-60.143. Lucas M, Kimmig M, Karalis G. / Do omega-3 polyunsaturated fatty acids preventcardiovascular disease? A review of the randomized clinical trials // Lipid Insights2013;6:13–20.144.
Mac Fadyen RJ, Lees KR, Reid JL. / Differences in first-dose response ofangiotenzine converting enzyme inhibition in congestive heart failure // Br Heart J.1991;66 (3):206–211.145. Maggioni AР, Anand I, Gottlieb SO et al. / Effects of Valsartan on Morbidity andMortality in Patients With Heart Failure Not Receiving Angiotensin-ConvertingEnzyme Inhibitors // J Am Coll Cardiol. 2002;40 (8):1414–1421.146. Major outcomes in high-risk hypertensive patients randomized to angiotensinconvertingenzymeinhibitororcalcium channelblocker vsdiuretic: theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT).
JAMA. 2002;288 (23):2981–2997.147. Mangiafico S, Costello-Boerrigter LC, Andersen IA et al. / Neutral endopeptidaseinhibition and the natriuretic peptide system: an evolving strategy in cardiovasculartherapeutics // Eur Heart J 2013;34:886–893.148. Mareev V, Lopatin Yu, Pervez Gh. / Possible mechanisms of positive beta-blockereffects in the treatment of dilated cardiomyopathy // Eur Heart J. 1993;14:94149. Massie BM, Armstrong PW, Cleland JG et al. / Toleration of high doses ofangiotensin-converting enzyme inhibitors in patients with chronic heart failure: resultsfrom the ATLAS trial: the Assessment of Treatment with Lisinopril and Survival //Arch Intern Med.
2001;161 (2):165–171.150. Massie B. / Final results jf the warfarin and antiplatelet trial in chronic heart failure(WATCH): a randomized comparison of warfarin, aspirin and clopidogrel // J Card Fail.2004;10 (2):101–112.136151. McKelvie RS, Rouleau J-L, White M et al. / Comparative impact of enalapril,candesartan or metoprolol alone or in combination on ventricular remodelling inpatients with congestive heart failure // Eur Heart J.
2003;24 (19):1727–1734.152. McKelvie RS, Yusuf S, Pericak D et al. / Comparison of candesartan, enalapril,and their combination in congestive heart failure: randomized evaluation of strategiesfor left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot StudyInvestigators / Circulation. 1999;100 (10):1056–1064.153. McMurray J. / Clinical practice.
Systolic heart failure // N Engl J Med. 2010. 362(3):228–238154. McMurray JJ, Ostergren J, Swedberg K et al. / Effects of candesartan in patientswith chronic heart failure and reduced leftventricular systolic function takingangiotensin-convertingenzyme inhibitors: the CHARM–Added trial // Lancet. 2003;362(9386):767–771.155. McMurray JJ, Packer M, Desai AS et al. / PARADIGM-HF Investigators andCommittees. Angiotensin-neprilysin inhibition versus enalapril in heart failure // N EnglJ Med 2014.371:993 –1004.156.
MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure(MERIT-HF) // Lancet. 1999;353 (9169):2001–2007.157. Messaoudi S., Azibani F., Delcayre C. et al. / Aldosterone, mineralocorticoidreceptor, and heart failure // Moll Cell Endocrinol 2012; 350: 266–72.158. Meyer JM., Rodvord KA. / Drug biotransformation by the cytochrome P450enzyme system // Infect Med. -1996; 13 (6): 452,459,463-464,523.159.
Mulder BA, Van Veldhuisen DJ, Crijns HJGM et al. / RACE II investigators.Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a posthoc analysis of the RACE II study // Eur J Heart Fail 2013. 15:1311–1318.160. Navookarasu NT, Rahman A, Abdullah I et al. / First-dose responce to angiotensinconverting enzyme inhibition in chronic cardiac failure: a Malaysian experience. // Int JClin Pract.
1999;53 (1):25–30.137161. Negro A, et al. / Liquorice-induced sodium retention. Merely an acquired conditionof apparent mineralocorticoid excess? A case report // Ann Ital Med Int 2013; 15(4):296–300162. Nguyen KN, Aursnes I, Kjekshus J. / Interaction between enalapril and aspirin onmortality after acute myocardial infarction: subgroup analysis of the Cooperative NewScandinavian Enalapril Survival Study II (CONSENSUS II) // Am J Cardiol. 1997;79(2):115–119.163.
NSAIDs and heart failure. Prescrire Int. 2001;10 (56):182–183.164. Ouyang A-J , Lv Y-N, Zhong H-L et al. / Meta-analysis of digoxin use and risk ofmortality in patients with atrial fibrillation // Am J Cardiol 2015;115:901–906.165. Packer M, Bristow MR, Cohn JN et al, for the U. S. Carvedilol Heart FailureStudy Group / The effect of carvedilol on morbidity and mortality in patients withchronic heart failure // N Engl J Med. 1996.
334 (21):1349–1355.166. Packer M, Carson P, Elkayam U, et al. / Effect of Amlodipine on the Survival ofPatients with Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. //JACC: Heart Failure. 2013;1(4):308–14. DOI:10.1016/j.jchf.2013.04.004167. Packer M, Coats AJ, Fowler MB et al.
/ Effect of carvedilol on survival in severechronic heart failure // N Engl J Med. 2001. 344 (22):1651–1658.168. Packer M, Lee WH, Kessler PD et al. / Identification of hyponatremia as a riskfactor for the development of functional renal insufficiency during converting enzymeinhibition in severe chronic heart failure // J Am Coll Cardiol. 1987;10 (4):837–844.169.
Packer M, Lee WH, Medina N et al. / Functional renal insufficiency during longterm therapy with captopril and enalapril in severe chronic heart failure // Ann InternMed. 1987;106 (3):346–354.170. Packer M, Poole-Wilson PA, Armstrong PW et al. / ATLAS Study Group.Comparative effects of low and high doses of the angiotensin-converting enzymeinhibitor, lisinopril, on morbidity and mortality in chronic heart failure // Circulation1999. 100:2312–2318.138171.
Pfeffer MA, McMurray JJ, Velazquez EJ et al. / Valsartan, captopril, or both inmyocardial infarction complicated by heart failure, left ventricular dysfunction, or both// N Engl J Med. 2003;349 (20):1893–1906.172. Phelan D, Thavendiranathan P, Collier P, Marwick TH / Aldosterone antagonistsimprove ejection fraction and functional capacity independently of functional class: ameta-analysis of randomised controlled trials // Heart. 2012;98 (23):1693–700.173.
Pitt B, Gheorghiade M, Zannad F et al. / Evaluation of eplerenone in the subgroupof EPHESUS patients with baseline left ventricular ejection fraction <or=30%. // Eur JHeart Fail. 2006;8 (3):295–301.174. Pitt B, Poole-Wilson PA, Segal R et al. / Effect of losartan compared with captoprilon mortality in patients with symptomatic heart failure: randomised trial: the LosartanHeart Failure Survival Study ELITE II // Lancet. 2000;355 (9215):1582–1587.175. Pitt B, Remme W, Zannad F et al. / Eplerenone, a selective aldosterone blocker, inpatients with left ventricular dysfunction after myocardial infarction // N Engl J Med.2003;348 (14):1309–1321176. Pitt B, White H, Nicolau J et al.
/ Eplerenone reduces mortality 30 days afterrandomization following acute myocardial infarction in patients with left ventricularsystolic dysfunction and heart failure // J Am Coll Cardiol. 2005;46 (3):425–431177. Ponikowski P., A. Voors A., D. Anker S. et al. / Рекомендации ESC подиагностике и лечению острой и хронической сердечной недостаточности 2016 //Российский кардиологический журнал. 2017ж. (1):7-81. DOI: 10.15829/1560-40712017-1-7-81178.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
